WaveMan
WaveMan · Company
CV · Capsovision, Inc
> Search tickers & screens ⌘K
LIVE
← All companies

CV CapsoVision (CV) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001378325
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
37
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $137.1K priced

What the filings say about CV

Insiders, 180 days
+$16.0M net bought
2 buyers · 1 seller · 0% of sales under a 10b5-1 plan

CapsoVision insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CapsoVision, Inc insiders bought a net $16.0M of stock across 8 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
HARARI ELIYAHOU ET AL
BUY
2026-09-23 SECtraded 2026-09-18
878,735
$5.0M
+11.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 17, 2026.
  • -3.9% median (-5.2% mean) 90-day return after 3 previous buys.
  • The trade is 62.9% of the 1,396,494 shares held after it.
  • 1 other insider bought within 30 days.
  • 37 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HARARI ELIYAHOU ET AL bought about $5.0M of CV on Sep 18, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 37 funds added in the latest 13F quarter.
HARARI ELIYAHOU ET AL
BUY
2026-09-23 SECtraded 2026-09-18
878,734
$5.0M
+11.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 17, 2026.
  • -3.9% median (-5.2% mean) 90-day return after 3 previous buys.
  • The trade is 100.0% of the 878,734 shares held after it.
  • 1 other insider bought within 30 days.
  • 37 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HARARI ELIYAHOU ET AL bought about $5.0M of CV on Sep 18, 2026; 1 other insider bought within 30 days and 37 funds added in the latest 13F quarter.
Shen Ching Hang
BUY
2026-09-23 SECtraded 2026-09-15
878,734
$5.0M
+11.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 12.1% of the 7,279,261 shares held after it.
  • 1 other insider bought within 30 days.
  • 37 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Shen Ching Hang bought about $5.0M of CV on Sep 15, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 37 funds added in the latest 13F quarter.
HARARI ELIYAHOU ET AL
BUY
2026-07-21 SECtraded 2026-07-17
61,068
$411.0K
-0.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 8, 2026.
  • -5.9% median (-5.9% mean) 90-day return after 2 previous buys.
  • The trade is 1.8% of the 3,343,119 shares held after it.
  • No other insider bought within 30 days.
  • 37 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HARARI ELIYAHOU ET AL bought about $411.0K of CV on Jul 17, 2026; 37 funds added in the latest 13F quarter.
HARARI ELIYAHOU ET AL
BUY
2026-07-10 SECtraded 2026-07-08
81,300
$495.1K
+10.8%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 26, 2026.
  • The trade is 2.5% of the 3,282,051 shares held after it.
  • No other insider bought within 30 days.
  • 37 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider HARARI ELIYAHOU ET AL bought about $495.1K of CV on Jul 8, 2026, the largest insider purchase at the company on our record; 37 funds added in the latest 13F quarter.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 3 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$16.0M over 180 days
+$15.0M over 90 days · +$16.0M of it by a 10%+ holder
more than 99% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
37 funds bought in last quarter
below 64% of Medical Devices
Revenue
+15.3% year over year
more than 60% of Medical Devices
Margin
-186.8% net margin
below 84% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.5% of the float short (float per yahoo 2026-10-26) · 5.4 days to cover · settled 2026-09-30
more than 57% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+40.3%12M
-7%+60%+127%+194%2025-102025-122026-022026-042026-062026-082026-10 2026-09-18 · HARARI ELIYAHOU ET AL bought $5.0M2026-09-15 · Shen Ching Hang bought $5.0M2026-09-18 · HARARI ELIYAHOU ET AL bought $5.0M2026-07-08 · HARARI ELIYAHOU ET AL bought $495.1K2026-07-17 · HARARI ELIYAHOU ET AL bought $411.0K2026-06-26 · HARARI ELIYAHOU ET AL bought $101.8K2026-06-08 · Imperial Joanne Carol sold $8.6K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CV: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
1,896,088 sh
$14.4M
VANGUARD CAPITAL MANAGEMENT LLC
1,058,468 sh
$8.0M
GEODE CAPITAL MANAGEMENT, LLC
578,482 sh
$4.4M
STATE STREET CORP
410,241 sh
$3.1M
VANGUARD PORTFOLIO MANAGEMENT LLC
240,425 sh
$1.8M

Congress trades in CV

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CV planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CV mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$868.8K position · as of 2026-06-30
0.1%
1290 VT Micro Cap Portfolio
$58.0K position · as of 2026-06-30
0.0%
GuideMark Small/Mid Cap Core Fund
$21.1K position · as of 2026-06-30
0.0%
Fidelity Small Cap Growth Index Fund
$247.0K position · as of 2026-06-30
0.0%
PD Small-Cap Growth Index Portfolio
$23.6K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$2.4M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $16.0M bought by insiders over 180 days, 37 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

CV financials

Revenue growth
+15.3%
XBRL, annual
Net margin
-186.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$13.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-214.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$27.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-212.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-321.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-8.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenue$13.6M$11.8M
Gross profit$7.2M$6.4M
Operating income-$25.5M-$19.9M
Net income-$25.3M-$19.9M
EPS (diluted)-1.03-9.85
Operating cash flow-$22.9M-$20.1M
SEC XBRL, fiscal years, as known on 2026-10-28

CV Stock Sonar score 5/7 axes

Find similar shapesCompare

CV ranks highest on insider conviction (87th percentile) and growth (60th), and lowest on profitability (5th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
5
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-212.2% · 7 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-321.9% · 3 pct, sector of 188
Growth
60
Inputs
  • Revenue growth, YoY+15.3% · 60 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
87
Inputs
  • Net Form 4 buying (codes P and S), 180d$16.0M · 99 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
36
Inputs
  • Funds adding, latest quarter37 · 36 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
  • Short interest, % of float+7.5% · 34 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CV filings, in plain words

Are CapsoVision insiders buying or selling CV?

In the 180 days to 2026-10-28, CapsoVision insiders were net buyers, a net $16.0M: $16.0M of purchases and $8.6K of sales reported on Form 4, by 2 buyers and 1 seller.

Read the full summary

In the 180 days to 2026-10-28, CapsoVision insiders were net buyers of CV, a net $16.0M across purchases and sales reported on Form 4 by 2 buyers and 1 seller. Most of that figure, $16.0M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies